NRIX · XBRL financial data

Nurix Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NRIX's year ends in late November)

In millions of dollars	Q4 FY23Nov 30, 2023	Q1 FY24Feb 29, 2024	Q2 FY24May 31, 2024	Q3 FY24Aug 31, 2024	Q4 FY24Nov 30, 2024	Q1 FY25Feb 28, 2025	Q2 FY25May 31, 2025	Q3 FY25Aug 31, 2025	Q4 FY25Nov 30, 2025	Q1 FY26Feb 28, 2026	Q2 FY26May 31, 2026	Q3 FY26Aug 31, 2026
Revenue	15*	17	—	—	—	—	—	—	—	—	—	—
Revenue from contracts with customers	15*	17	12	13	13*	18	44	8	14*	6	9	673
Research and development	50*	50	49	55	67*	70	78	86	83*	84	88	79
General and administrative	11*	12	12	12	11*	12	14	13	14*	15	16	34
Total operating expenses	60*	62	61	67	78*	81	92	99	97*	99	103	114
Operating income (loss)	(45)*	(45)	(49)	(55)	(65)*	(63)	(48)	(91)	(83)*	(92)	(94)	559
Income tax expense (benefit)	0*	0	0	0	0*	0	1	0	0*	0	(0)	14
Net income (loss)	(42)*	(42)	(45)	(49)	(59)*	(56)	(43)	(86)	(78)*	(87)	(90)	550
Earnings per share, basic USD per share	(0.77)*	(0.76)	(0.71)	(0.67)	(0.75)*	(0.67)	(0.52)	(1.03)	(0.82)*	(0.79)	(0.81)	4.93
Earnings per share, diluted USD per share	(0.77)*	(0.76)	(0.71)	(0.67)	(0.75)*	(0.67)	(0.52)	(1.03)	(0.82)*	(0.79)	(0.81)	4.73
Weighted average shares, basic millions of shares	55*	55	62	73	78*	84	84	84	95*	110	111	112
Weighted average shares, diluted millions of shares	55*	55	62	73	78*	84	84	84	95*	110	111	116

Fiscal quarters (NRIX's year ends in late November)

In millions of dollars	Q4 FY23Nov 30, 2023	Q1 FY24Feb 29, 2024	Q2 FY24May 31, 2024	Q3 FY24Aug 31, 2024	Q4 FY24Nov 30, 2024	Q1 FY25Feb 28, 2025	Q2 FY25May 31, 2025	Q3 FY25Aug 31, 2025	Q4 FY25Nov 30, 2025	Q1 FY26Feb 28, 2026	Q2 FY26May 31, 2026	Q3 FY26Aug 31, 2026
Cash and cash equivalents	55	50	117	99	110	76	84	78	247	71	68	720
Accounts receivable	—	—	—	—	0	—	19	—	0	—	—	20
Prepaid and other current assets	8	7	7	8	10	14	11	12	14	14	13	35
Total current assets	296	251	450	456	619	564	515	441	607	554	456	1,104
Property and equipment, net	17	18	19	17	18	18	19	20	22	22	20	19
Right-of-use asset	31	29	29	27	28	26	50	53	51	52	50	49
Total assets	356	313	511	514	669	615	592	522	688	636	536	1,195
Accounts payable	6	6	3	4	11	8	6	9	11	10	12	33
Total current liabilities	87	88	81	86	96	90	76	82	86	92	72	131
Lease liability, non-current	23	22	21	21	20	20	47	53	53	55	55	62
Total liabilities	155	144	140	137	142	134	144	150	149	155	133	227
Accumulated deficit	(545)	(587)	(631)	(680)	(739)	(795)	(839)	(925)	(1,003)	(1,090)	(1,180)	(630)
Total stockholders' equity	200	169	371	377	527	481	448	372	539	481	403	968
Total liabilities and equity	356	313	511	514	669	615	592	522	688	636	536	1,195
Common shares outstanding (cover page) millions of shares	49	49	64	71	76	76	76	77	103	103	104	109

Fiscal quarters (NRIX's year ends in late November)

In millions of dollars	Q4 FY23Nov 30, 2023	Q1 FY24Feb 29, 2024	Q2 FY24May 31, 2024	Q3 FY24Aug 31, 2024	Q4 FY24Nov 30, 2024	Q1 FY25Feb 28, 2025	Q2 FY25May 31, 2025	Q3 FY25Aug 31, 2025	Q4 FY25Nov 30, 2025	Q1 FY26Feb 28, 2026	Q2 FY26May 31, 2026	Q3 FY26Aug 31, 2026
Net income (loss)	(42)*	(42)	(45)	(49)	(59)*	(56)	(43)	(86)	(78)*	(87)	(90)	550
Stock-based compensation	8*	8	9*	9*	9*	9	10*	10*	9*	9	11*	11*
Net cash from operating activities	27*	(42)	(40)*	(42)*	(49)*	(61)	(63)*	(57)*	(68)*	(72)	(97)*	616*
Purchases of property and equipment	3*	3	2*	2*	2*	3	3*	3*	5*	1	2*	1*
Net cash from investing activities	(14)*	36	(131)*	(21)*	(141)*	26	71*	50*	0*	(124)	93*	32*
Proceeds from issuing common stock	0*	—	—	42*	199*	0	0*	0*	0*	18	0*	0*
Net cash from financing activities	0*	2	238*	46*	201*	1	0*	1*	236*	20	0*	5*
Net change in cash	12*	(5)	67*	(18)*	11*	(34)	8*	(6)*	169*	(176)	(4)*	652*

The peer list for this company is being put together from its industry's latest filings. Reload the page in a minute to see it.

Not investment advice. Not affiliated with the U.S. SEC.